Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients

Sandeep K. Mallipattu, John C. He, Jaime Uribarri

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

It has been nearly 100years since the first published report of advanced glycation end products (AGEs) by the French chemist Maillard. Since then, our understanding of AGEs in diseased states has dramatically changed. Especially in the last 25years, AGEs have been implicated in complications related to aging, neurodegenerative diseases, diabetes, and chronic kidney disease. Although AGE formation has been well characterized by both in vitro and in vivo studies, few prospective human studies exist demonstrating the role of AGEs in patients on chronic renal replacement therapy. As the prevalence of end-stage renal disease (ESRD) in the United States rises, it is essential to identify therapeutic strategies that either delay progression to ESRD or improve morbidity and mortality in this population. This article reviews the role of AGEs, especially those of dietary origin, in ESRD patients as well as potential therapeutic anti-AGE strategies in this population.

Original languageEnglish
Pages (from-to)529-538
Number of pages10
JournalSeminars in Dialysis
Volume25
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Dive into the research topics of 'Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients'. Together they form a unique fingerprint.

Cite this